Chowdhury, Namara MariamNiasa, Jannatul Ferdous2023-01-182023-01-1820222022-05ID 18146073http://hdl.handle.net/10361/17766Cataloged from PDF version of thesis.Includes bibliographical references (pages 41-45).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.Triple-negative breast cancer is defined as breast cancer that lacks estrogen, progesterone, and the human epidermal growth factor receptor 2. (TNBC). This malignancy accounts for 15–20 percent of all breast cancers and is of particular interest for study because of its clinically problematic low treatment response and highly invasive features. Due to the lack of particular treatment options for TNBC, conventional therapy such as adjuvant and neoadjuvant therapy, surgery, immunotherapy, and radiation therapy are frequently used. The focus of this review is to provide information related to TNBC diagnosis and survival rate, biomarkers, different signaling pathways as well as current and investigation therapies, prognosis, and some advanced research about drugs and therapies. Researchers working in the area may find the data offered in this publication useful in obtaining general and specific information to increase their understanding of TNBC and provide appropriate disease management in the future.45 pagesenBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.TNBCHER-2 receptorsAnti-cancer therapeuticsSignaling pathwaysBreast--Cancer--PatientsBreast--Cancer--TreatmentThesis